Jaksokuvaus
In this episode of the a16z bio journal club, we cover one of the key clinical trials that supported the recent FDA approval of the first prescription video game. The game was developed by Akili Interactive, is called EndeavorRx, and is now a clinically-validated therapy for improving attention in children with Attention Deficit Hyperactivity Disorder (ADHD). But how does a game improve attention? How does a clinical trial evaluate the efficacy of a game? And what are the pros and cons of a video game as compared to traditional pharmacological therapies for ADHD? Bio deal team partner Justin Larkin and Lauren Richardson delve into these questions and more in their discussion of this clinical trial:“A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial” in Lancet Digital Health (April 2020) by Scott H Kollins, Denton J DeLoss, Elena Cañadas, Jacqueline Lutz, Robert L Findling, Richard S E Keefe, Jeffery N Epstein, Andrew J Cutler, and Stephen V Faraone.a16z bio Journal Club (part of the a16z Podcast), curates and covers recent advances from the scientific literature -- what papers we’re reading, and why they matter from our perspective at the intersection of biology & technology (for bio journal club). You can find all these episodes at a16z.com/journalclub.
Uusimmat jaksot
The GenAI 100: The Apps that Stick
Finding a Single Source of AI Truth With Marty Chavez From Sixth Street
A Big Week in AI: GPT-4o & Gemini Find Their Voice
Remaking the UI for AI
How Discord Became a Developer Platform
Securing the Black Box: OpenAI, Anthropic, and GDM Discuss
Can AI Advance Science? DeepMind's VP of Science Weighs In
Next-Gen Gaming: AI Souls, Real-time Culture, Personalized Avatars
Why America Must Lead in AI Investment with Senator Young (R-IN)
